Erector Spinae Block for Spine Surgery

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to determine whether or not the addition of liposomal bupivacaine in an ESP block will have long term benefits for patients undergoing lumbar spinal fusion surgery. Given previous studies found long term benefits from liposomal bupivacaine, the hypothesis is that patients will have decreased opioid usage and improved pain scores when compared to a standard ESP block with plain 0.25% bupivacaine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Icahn School of Medicine at Mount Sinai
• Treatments: Bupivacaine

Criteria

Inclusion criteria:

• Adults aged greater than or equal to 18 years old and less than or equal to 85 years old.

• Patients who are scheduled to undergo lumbar spinal surgery (1-2 level) and willing and able to provide informed consent.

Exclusion criteria:

• Patients with a history of chronic opioid use for > 3 months including but not limited to fentanyl, morphine, oxycodone, methadone.

• Patients with known allergy or intolerance to any drug used in the study including local anesthetics and total intravenous anesthesia medications.

• Patients with a history of alcohol or drug abuse.

• Patients with a history of intolerance of nonsteroidal anti-inflammatory drugs.-Patients with hepatic insufficiency.

• Patients with renal insufficiency.

• Patients who are pregnant.

• Patients with American Society of Anesthesiologists physical status of 4 or greater.

• Patients on immunosuppressive therapy. Pregnant patients.